Strides Pharma Science Limited (STAR) announced the positive USFDA Establishment Inspection Report for its Bengaluru facility, reinforcing its commitment to.
Strides Pharma Science Limited (STAR) reports Q1 FY27 results with revenue up 13% YoY, driven by 17% growth in Ex-US markets.
Strides Pharma Science Limited (STAR) partners with Ascent Capital to unlock value in Pivot Path, realizing ₹1,000m while retaining 20% stake.
Strides Pharma Science Limited (STAR) reveals robust FY26 results with a 50% YoY growth in operational PAT and a 21% rise in Ex-US markets.